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Background: Anti-NMDA-encephalitis is caused by antibodies against the N-methyl-D-aspartate receptor (NMDAR)
and characterized by a severe encephalopathy with psychosis, epileptic seizures and autonomic disturbances. It
predominantly occurs in young women and is associated in 59% with an ovarian teratoma.
Results: We describe effects of cerebrospinal fluid (CSF) from an anti-N-methyl-D-aspartate receptor (NMDAR)
encephalitis patient on in vitro neuronal network activity (ivNNA). In vitro NNA of dissociated primary rat cortical
populations was recorded by the microelectrode array (MEA) system.
The 23-year old patient was severely affected but showed an excellent recovery following multimodal
immunomodulatory therapy and removal of an ovarian teratoma. Patient CSF (pCSF) taken during the initial weeks
after disease onset suppressed global spike- and burst rates of ivNNA in contrast to pCSF sampled after clinical
recovery and decrease of NMDAR antibody titers. The synchrony of pCSF-affected ivNNA remained unaltered during
the course of the disease.
Conclusion: Patient CSF directly suppresses global activity of neuronal networks recorded by the MEA system. In
contrast, pCSF did not regulate the synchrony of ivNNA suggesting that NMDAR antibodies selectively regulate
distinct parameters of ivNNA while sparing their functional connectivity. Thus, assessing ivNNA could represent a
new technique to evaluate functional consequences of autoimmune encephalitis-related CSF changes.
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Anti-NMDA-antibodyBackground
Anti-N-methyl-D-aspartate receptor (NMDAR) encephal-
itis is a recently described disorder characterized by psych-
osis, epileptic seizures, inflammatory cells in cerebrospinal
fluid (CSF) and NMDAR-binding antibodies detectable in
serum and CSF [1]. Initially described as a paraneoplastic
disease that mostly affects young women with ovarian tera-
tomas [1-3], latest studies report the occurrence of anti-
NMDAR encephalitis in older patients and children with
or without the presence of a tumor [2,4,5]. Impaired con-
sciousness, obtundation and autonomic disturbances can
be lifethreatening. Treatment recommendations include* Correspondence: sabine.jantzen@uk-koeln.de
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reproduction in any medium, provided the orremoval of the tumor and immunosuppressive strategies
like administration of methylprednisolone, cyclophospha-
mide, immunoglobulins, plasma exchange or rituximab.
While 75% of treated patients have been found to recover
completely or retain only mild deficits, 25% remain se-
verely disabled and few even die [3]. Interestingly, clinical
improvement seems to correlate with a reduction of
NMDAR antibody titers in CSF and serum [2].
The diagnostically defining anti-NMDAR antibodies
bind to the surface of CNS neurons. It was shown that
the binding epitope is part of the NR1-subunit of the
NMDAR on postsynaptic dendrites in the forebrain and
hippocampus [1-3]. After capping of NMDARs by
anti-NMDAR antibodies, NMDARs are internalized,
and consecutively, synaptic NMDAR cluster density
decreases. This process is reversible and cell death is not
observed [6]. Electrophysiological investigations showed
that patients’ CSF containing anti-NR1 antibodiesl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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citatory post synaptic currents (mEPSCs) while AMPA-
mediated mEPSCs remained unaltered [6]. Thus,
anti-NR1 antibody-mediated internalization of NMDARs
directly and specifically affects NMDAR-mediated cur-
rents. GABA receptors were not impacted demonstrating
a specific hypo-functional effect of patients’ CSF on
NMDARs. This concept is in line with the observation
that NMDAR dysfunction contributes to several neuro-
psychological disorders like psychosis and that numbers
of NMDARs are regulated in response to neuronal ac-
tivity [7]. Notably, ketamine acts as an NMDAR antag-
onist and induces behavioral abnormalities similar to the
symptoms found in NMDAR encephalitis [8,9]. To
investigate effects of NMDAR antibodies containing CSF
on a more complex system whose functionality depends
on different neurotransmitter-specific neurons like gluta-
matergic and GABAergic neurons as well as excitatory
and inhibitory synapses which are all supported by astro-
cytes, we made use of a mixed, dissociated neural popula-
tion generated from rat cortex whose electrophysiological
activity was detected by microelectrode arrays (MEAs)
[10]. After approximately 3 weeks in culture, neural popu-
lations had developed a dense neurite network, the pre-
requisite for the observed spontaneous population
bursting. MEAs are composed of multiple, spatially dis-
tributed extracellular electrodes that are able to measure
spike and burst activity at different sites of the population.
Here, we report that CSF from a young woman with
anti-NMDAR encephalitis suppressed in vitro-neuronal
network activity in the acute stage of the disease and
that this effect was reversible when the patient
recovered upon removal of an ovarian teratoma and
subsequent immunosuppression. Network suppression
became manifest in significantly reduced spike and
burst rates while network synchrony was preserved.
Interestingly, this reaction pattern is also observed
when functional neuronal networks are exposed to a
specific NMDA receptor antagonist [10].
Case
In April 2010, a previously healthy 23-year old woman
was admitted to our hospital because of a first general-
ized epileptic seizure. The family of the patient reported
about a slight personality change with inappropriate dis-
trustful and jealous behavior that had occurred in previ-
ous 4 weeks before admission. Neurological examination
was unremarkable and there were no signs of a marked
neuropsychiatric or mental disorder. Cerebral magnetic
resonance imaging (MRI) was normal. CSF examination
revealed a pleocytosis of 72 white blood cells (WBC) /μl,
an intrathecal synthesis of immunglobulin M and positive
oligoclonal bands (OCBs). All polymerase chain reaction
(PCR) -tests against neurotropic viruses including herpessimplex virus 1+2, cytomegaly, Epstein-Barr virus, human
herpes virus 6, varicella zoster virus, adenovirus, JC virus,
and coxsackie virus remained negative. The electro-
encephalogram (EEG) showed bi-frontal slowing but no
epileptic discharges. During the following 12 days the pa-
tient progressively developed a dysexecutive syndrome
and exhibited a bizarre and disorganized behavior despite
treatment with high doses of valproate (1200 mg/day) and
lorazepam (2 mg/day) (Figure 1). Furthermore, the patient
developed signs of delusion, pathological distrust and
diminished speech production necessitating transfer of the
patient to a protected ward. The patients psychopatho-
logical symptoms deteriorated further and she developed
severe psychosis including mutism, alternating phases of
agitation and akinesia as well as fluctuating levels of
consciousness. In the third week, the patient developed
right-sided orofacial myocloniform dyskinesia and eye-
movement abnormalities. The patient was severely
impaired on neuropsychological testing and ultimately un-
responsive (Figure 2). While cerebral MRI and CSF
remained largely unaltered, multiple EEG investigations
showed severe bi-hemispheric slowing. At that time, anti-
NMDAR antibodies in serum and CSF (both 1:2560) and
an ovarian tumor were detected. Antiinflammatory treat-
ment with 1000 mg methylprednisolone per day was
initiated. After transfer to the intensive care unit, the pa-
tient received five cycles of plasma exchange. To prevent a
rebound, intravenous immunglobulins (30 g/day for
3 days) were administered. For long-term B-cell depletion,
rituximab at a dose of 1000 mg was given. Also, the right
side ovarian tumor was surgically removed. Histology
revealed a mature teratoma without microscopic struc-
tures of nervous tissue. Intravenous methylprednisolone
treatment was followed by oral therapy with 75 mg/day
(Figure 1).
Thereafter, the patient improved continuously. Five
weeks after admission, the patient was fully orientated and
showed an adequate communication. Physical mobilization
was possible. Rare periods of reduced consciousness with
agitation and a constant subtle delusion with distrusting
behavior still remained. CSF control investigation showed
normalized parameters (WBC <1/μl, OCB negative) and a
reduction of the anti-NMDAR antibody titer in serum to
1:320 and in CSF to 1:100.
At follow-up investigation three months later, the
patient did not present any neurological or psychiatric
abnormalities. Neuropsychological examination revealed
a significant improvement (Figure 2). CSF parameters
were normal and NMDAR antibodies had declined
further to titers of 1:100 in serum and to 1:10 in CSF.
Antipsychotic medication was tapered, but antiepileptic
therapy with 2000 mg levetiracetam was recommended
for further 6 months. She continued her academic study
of psychology.
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Figure 1 Time course of disease. Therapeutic procedures, CSF antibody titers and representative spike raster plots (x-axis: recording time in
seconds; y-axis: channel number) of MEA experiments are given in relation to the time after initial hospitalization of the patient. Time points (T1-T3) of
psychological tests are given.
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Measurement of NMDAR antibody titers
Anti-NMDAR antibodies in both, CSF and serum, were
measured by antigen-antibody-reaction with indirect im-
munofluorescence on NR1-transfected Human Embryonic
Kidney cells (HEK cells) [6] as well as rat hippocampal
and cerebellar slices (HEK cells and all slices from
Euroimmun, Lübeck, Germany). The patient has given
written informed consent to using the CSF samples for
scientific purpose and publication of the case details.
Ethics approval by the ethics committee (Institutional
Review Board) of Düsseldorf University was obtained
(3785). Anti- NMDAR antibodies were measured in
patients´ samples of CSF and serum taken four days and
three, five and 18 weeks after admission.
Polymerase chain reaction (PCR) -tests against
neurotropic viruses
PCR-tests for neurotropic viruses were performed with
the standard technique “TaqMan realtime” and revealed
no presence of herpes simplex virus 1+2, cytomegalovirus,Epstein-Barr virus, human herpes virus 6, varicella zoster
virus, adenovirus, JC virus, and coxsackie virus in the
cerebrospinal fluid.
Cell culture
Cortical cells were freshly prepared from embryonic day
18 Wistar rats. Cell preparation and animal care were
performed in compliance with the German Animal Pro-
tection law (State Office, Environmental and Consumer
Protection of North Rhine-Westphalia). Permission/
Ethic approval was granted by the Institutional Review
Board of Düsseldorf University (O/5/2009). Dissociated
cortical cells were isolated and collected in ice cold N2
medium (Invitrogen, Karlsruhe, Germany) and trypsi-
nized for 10 minutes. After dual centrifugation for 1 mi-
nute at 2000 and 5 minutes for 1500 repeats per minute,
cells were resuspended in N2-supplemented Neurobasal
medium (Invitrogen) containing 5% fetal calf serum
(Fisher Scientific, Schwerte, Germany) and plated at a
density of 150 × 103/cm2 onto poly-D-lysine- and laminin-



























































Figure 2 The neuropsychological course. At time point 1 (T1) the patient suffered from acoustic illusions, incoherence of thought,
psychomotor agitation, mood instability and speech dysfunction (perseveration and neologisms). Mini-Mental-Status-Examination (MMSE: 22/30)
showed clinically relevant cognitive impairment. Psychomotor speed assessed by the Trail-Making-Test-A (TMT-A) was average, cognitive
flexibility/task switching (TMT-B), verbal memory span, working memory and semantic category verbal fluency were below average (percentile
rank < 16). At T2, formal neuropsychological testing was not feasible due to clouding of consciousness, mutism and pronounced psychomotor
slowing. Moreover, the patient displayed undirected utilization behaviour suggestive of severe frontal lobe dysfunction. At T3, neuropsychological
functioning was considerably improved. MMSE was inconspicuous (30/30). With the exception of discrete impairment regarding verbal memory
span, formal neuropsychological testing revealed above average psychomotor speed (TMT-A) and cognitive flexibility (TMT-B), average working
memory and executive functioning as measured by semantic category verbal fluency. Interestingly, phonemic verbal fluency, which is considered
to involve frontal cognitive control even more than semantic category tasks, was below average, possibly hinting at a subtle residual
executive impairment.
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week. After approximately 3 weeks in vitro, cultures devel-
oped a dense synaptically connected neuronal network and
reached stable electrophysiological properties including
population bursting. Functional neuronal networks were
used for recordings when they reached a minimum burst-
ing activity of 20 bursts per minute. MEA experiments
were performed between 26 and 64 days in vitro (see
below), a time window of preserved synchronous popula-
tion bursting. Earlier immunocytochemical experiments of
identical cell preparations [11] demonstrated that neural
population consists of glial fibrillary acid protein-positive
astrocytes, vesicular glutamate transporter 2 -positive glu-
tamatergic neurons and γ-aminobutyric acid-positive neu-
rons. Extensive immunocytochemical control experiments
for this and other studies confirmed the above mentioned
cellular phenotypes which were stable along multiple pre-
parations. For this study, 3 different preparations were used
and randomly assigned to the experiments.
MEA measurements and experimental design
To investigate the potential effect of the patients´ CSF
(pCSF) on electrophysiological neuronal network parameters
like global network activity and the synchrony ofpopulation bursts, pure pCSF of 3 different time points
during the course of the disease was administered to at
least 4 independent microelectrode arrays (MEAs, Multi
Channel Systems, Reutlingen, Germany), respectively.
Control experiments with independent MEAs (n=4) were
performed using CSF of a healthy person (cCSF). In detail,
for MEA experiments that were all continuously per-
formed outside the incubator for 30–40 minutes, cell cul-
ture medium was first replaced against aCSF (aCSF;
150 mM NaCl, 1 mM CaCl2, 3 mM KCl, 1 mM MgCl2,
10 mM N-2-hydroxyethylpiperazine-N-2-ethanesulfonic
acid, 10 mM glucose, pH 7.4; Sigma, St. Louis, MO). Net-
work activity was then recorded for the next 15 minutes
and averaged for one data point. Then, aCSF was replaced
against pure pCSF or cCSF and network activity was again
measured for 15 minutes and averaged. The pH was
adjusted (HEPES buffer) to 7.4 in all solutions (aCSF,
pCSF, cCSF) prior to every experiment and remained con-
stant (+/− pH 0.1) for at least 30 minutes outside the incu-
bator. In Figure 3a, relative values of cCSF/aCSF or pCSF/
aCSF are given. In Figure 3b, absolute values are given.
Experiments on every single MEA were performed in a
standardized design (aCSF for 15 minutes – cCSF or pCSF
for 15 minutes). For statistical analyses, the paired student
ab
Figure 3 The microelectrode arrays. In a), diagrams illustrate effects of cCSF and pCSF collected at different time points during the course of
the disease. Stars illustrate significances against CSF taken 4 days after admission (May 1st) or five weeks after admission (June 1st). In b), diagrams
illustrate quick effects of cCSF (left) or pCSF (middle and right) in comparison to aCSF over a time course of 45 minutes (15 minutes in aCSF,
15 minutes in pCSF and 15 minutes again in aCSF). Bars represent standard error of the mean.
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standard error of means. All data analyses have been per-
formed with GraphPadPrism, version 4.0.
To measure the electrophysiological activity of neuronal
populations, MEAs with a square grid of 60 planar Ti/TiN
electrodes (30-μm diameter, 200-μm spacing) were used.
Signals from all 60 electrodes were simultaneously sampled
at 25 kHz, visualized and stored using the standard soft-
ware MC_Rack provided by Multi Channel Systems. Spike
and burst detection was performed off-line by custom-
built software (Result, Düsseldorf, Germany). Details of
data collection are given elsewhere [12]. Temporal syn-
chrony of spike activity across electrodes was determined
by binning all spikes into time intervals of 10 milliseconds.
For all pairs of active electrodes, the agreement coefficient
Cohen’s kappa was calculated, which measures the degreeof coincidence of spikes on both electrodes exceeding the
chance-expected coincidence assuming uncorrelated spike
activity [13]. The average kappa of all electrode pairs was
calculated as measure of overall synchrony of a recording.
Theoretically, kappa may vary in the range −1 to +1.
Results
Patient CSF taken 4 days and 5 weeks after admission
(both with NMDAR antibody titers of 1:100) induced a
significant suppression of global activity markers (spike
rate and burst rate) in spontaneously bursting in vitro-
cortical neuronal networks in comparison to CSF from a
healthy control person (Figure 3a, left and middle dia-
gram). Unfortunately, the CSF sample with antibody titers
of 1:2560 (third week after admission) was too small pre-
cluding further analysis. CSF from the same patient
Jantzen et al. BMC Neuroscience 2013, 14:17 Page 6 of 7
http://www.biomedcentral.com/1471-2202/14/1718 weeks after admission to hospital, after therapy and in
greatly improved clinical condition did not suppress these
parameters any longer. The NMDAR antibody titer at this
time point was 1:10. Interestingly, the degree of network
synchrony was unaltered under the influence of all differ-
ent pCSF probes (Figure 3a, right diagram). Furthermore,
we could demonstrate a quick suppressive effect of pCSF
on spikerates within the first 15 minutes after application
of pCSF, that was taken five weeks after admission
(Figure 3b, right diagram). This investigation was done in
comparison to artificial CSF (aCSF) in a paired fashion on
the same MEA. Patient CSF taken 4 days after admission
only tendentially decreased quickly the spikerate in com-
parison to aCSF (Figure 3b, middle diagram) showing that
the speed of network alterations might vary between pCSF
probes that indeed showed identical NMDAR antibody
titers but that were taken at different time points during
the course of the disease. In contrast, application of CSF
of a healthy control (cCSF) typically increased the spike-
rate (Figure 3b, left diagram).
Discussion
We present a case with severe paraneoplastic anti-
NMDAR encephalitis and complete recovery after surgi-
cal removal of the ovarian teratoma and multimodal
immunomodulatory therapy. High-dose methylpredniso-
lone treatment, plasma exchange and administration of
immunoglobulins rapidly reversed the downhill course
and allowed the patient to recover. Most likely, B-cell de-
pletion with rituximab sustained the subsequent complete
recovery. Following the complete clinical recovery, OCBs
were no longer detectable. Disappearance of OCBs from
the CSF after treatment is highly unusual. As NMDAR
antibody titers, also at the late time point, were still meas-
urable, it is unlikely that OCBs represented a specific anti-
NMDAR immune response.
It was previously found that NMDAR auto-antibodies
lead to receptor internalization and, consecutively, a
hypo-functional state including decreased NMDAR cur-
rents [6]. Here, we were able to show that the patient’s
CSF suppresses global activity in functional neuronal net-
works while synchrony of population bursts remained un-
altered. Recently published results demonstrated that
modulation at the NMDA receptor can significantly influ-
ence in vitro-neuronal network activity (ivNNA) [10,14].
Importantly, NMDAR modulation was shown to inversely
influence burst rates and the degree of synchrony of the
network which is expressed by the kappa value [14]. Con-
cerning suppression of NMDAR function, the NMDA-
receptor antagonist DL-2-Amino-5-phosphono-pentanoic
acid (AP-5) can supress the burst rate while preserving
the kappa value [10]. This directly illustrates that a hypo-
functional state of NMDA receptors exerts complex reac-
tions within a system that depends on a variety ofdifferent electrophysiological players. And this suggests
that rhythmic activity of neuronal networks can still be
present under the influence of suppressing NMDAR auto-
antibodies. An electrophysiological constellation combin-
ing a hypo-functional state including decreased NMDAR
activity with preserved rhythmic network activity might
then relate to the clinical hallmarks that comprise psych-
osis and epileptic seizures illustrating the importance of
measuring pharmacological effects in a more complex sys-
tem that mimics basic features of oscillating brain activity.
Although the system used in our study represents artificial
in vitro-neuronal network activity, a body of work has
described its activity under different extracellular compo-
sitions that in summary suggest a physiological-like activ-
ity of population bursting under balanced extracellular
conditions. Addition of neuroactive substances, e.g. acting
on glutamatergic or GABAergic synapses or modulating
voltage-dependant ion channels, change that activity
which is described in multiple reports [10,12,14,15]. Thus,
pathological-like conditions of this artificial in vitro system
can be defined.
The pCSF-related effects observed in this study resolved
in parallel to clinical improvement and a reduction of the
antibody titer to 1:10. We could also demonstrate a fast
suppressive effect of pCSF on network activity within the
first 15 minutes after pCSF application in comparison to
aCSF suggesting that next to NMDAR capping and intern-
alization, pCSF might additionally induce a rapidly evolving
dysfunction of neuronal network activity. The reversibility
and functional dynamics of neuronal network activity under
the influence of pCSF shown here and the course of
anti-NMDAR antibody titers in our patient strengthen the
notion that anti-NMDAR antibodies mediate this neuro-
psychiatric syndrome. However, it remains to be elucidated
if antibodies can indeed exert such a fast functional effect
on NMDA receptors as antibody binding usually needs
some time. Our report has several shortcomings: First, we
only investigated one pCSF. Second, as a variety of dif-
ferent drugs were administered in the course of the
disease, additional drug-related effects cannot be com-
pletely excluded. However, as benzodiazepines were
administered only during the second collection of lum-
bar CSF, we consider benzodiazepine effects on neur-
onal network activity unlikely. Third, we were not able
to directly attribute the observed effects to NMDAR
autoantibodies as the limited volume of the CSF
probes rendered further pCSF-based investigations im-
possible. Thus, further experiments with a higher
number and larger volume of CSF probes from differ-
ent NDMAR encephalitis patients are needed.
Conclusion
We described a method to assess functional conse-
quences of pathologically altered CSF specimens from a
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cephalitis antibodies against surface epitops are continu-
ously discovered newly, this method can serve to
investigate CSF specimens from so far antibody-negative
limbic encephalitis patients.
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